Protein profiling in human sera for identification of potential lung cancer biomarkers using antibody microarray
- PMID: 20017155
- DOI: 10.1002/pmic.200800777
Protein profiling in human sera for identification of potential lung cancer biomarkers using antibody microarray
Abstract
To identify potential biomarkers of lung cancer (LC), profiling of proteins in sera obtained from healthy and LC patients was determined using an antibody microarray. Based on our previous study on mRNA expression profiles between patients with LC and healthy persons, 19 proteins of interest were selected as targets for fabrication of an antibody microarray. Antibody to each protein and five nonspecific control antibodies were spotted onto a hydrogel-coated glass slide and used for profiling of proteins in sera of LC patients in a two-color fluorescence assay. Forty-eight human sera samples were analyzed, and expression profiling of proteins were represented by the internally normalized ratio method. Six proteins were distinctly down-regulated in sera of LC patients; this observation was validated by Wilcoxon test, false discovery rate, and Western blotting. Blind test of other 32 human sera using the antibody microarray followed by hierarchical clustering analysis revealed an approximate sensitivity of 88%, specificity of 80%, and an accuracy of 84%, respectively, in classifying the sera, which supports the potential of the six identified proteins as biomarkers for the prognosis of lung cancer.
Similar articles
-
Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers.Proteomics. 2003 Jan;3(1):56-63. doi: 10.1002/pmic.200390009. Proteomics. 2003. PMID: 12548634
-
Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis.BMC Cancer. 2005 Aug 23;5:110. doi: 10.1186/1471-2407-5-110. BMC Cancer. 2005. PMID: 16117833 Free PMC article.
-
Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.Am J Clin Oncol. 2008 Apr;31(2):133-9. doi: 10.1097/COC.0b013e318145b98b. Am J Clin Oncol. 2008. PMID: 18391596
-
Application of serum SELDI proteomic patterns in diagnosis of lung cancer.BMC Cancer. 2005 Jul 20;5:83. doi: 10.1186/1471-2407-5-83. BMC Cancer. 2005. PMID: 16029516 Free PMC article.
-
Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens.J Proteome Res. 2004 Mar-Apr;3(2):261-7. doi: 10.1021/pr049971u. J Proteome Res. 2004. PMID: 15113102 Review.
Cited by
-
Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis.PLoS One. 2017 Jul 27;12(7):e0182117. doi: 10.1371/journal.pone.0182117. eCollection 2017. PLoS One. 2017. PMID: 28750095 Free PMC article.
-
Integrative proteomic profiling of protein activity and interactions using protein arrays.Mol Cell Proteomics. 2012 Nov;11(11):1167-76. doi: 10.1074/mcp.M112.016964. Epub 2012 Jul 26. Mol Cell Proteomics. 2012. PMID: 22843993 Free PMC article.
-
Emerging non-invasive detection methodologies for lung cancer.Oncol Lett. 2020 May;19(5):3389-3399. doi: 10.3892/ol.2020.11460. Epub 2020 Mar 12. Oncol Lett. 2020. PMID: 32269611 Free PMC article. Review.
-
Relative quantification of several plasma proteins during liver transplantation surgery.J Biomed Biotechnol. 2011;2011:248613. doi: 10.1155/2011/248613. Epub 2011 Dec 10. J Biomed Biotechnol. 2011. PMID: 22187521 Free PMC article.
-
Identification of Serum Peptidome Signatures of Non-Small Cell Lung Cancer.Int J Mol Sci. 2016 Mar 31;17(4):410. doi: 10.3390/ijms17040410. Int J Mol Sci. 2016. PMID: 27043541 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical